The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, which are known oncogenic drivers. The study will also
Both of these diseases are ultra-rare, with prevalences in the United States believed to be approximately 3,000 and 1,000-1,500 patients, respectively. Catalyst CEO Patrick McEnany said: "The completion
Under this collaboration, XL-protein will apply its proprietary PASylation® technology for drug half-life extension to one Easton target. XL-protein will assume responsibility for early preclinical development activities, Easton
Founding partners participating in the program include: argenx, Crystal Bioscience and Sevion Therapeutics. The program combines Tetragenetics’ unique and proprietary antigen production capabilities with each partner’s novel antibody
Perrigo was the authorized generic distributor of these products from 2005 to 2013 before the agreement was terminated. Generic and brand sales of Retin-A, which is indicated for
This trial will evaluate the safety and efficacy of SPI-2012 as a treatment for chemotherapy-induced neutropenia in patients with breast cancer, and will serve as the basis for
Using the Sinequa Platform, UCB is able to more effectively find data sets that will help expedite responding to questions arising in the lifecycle of drug development, in
By combining CapellaBio’s SMarTR computational analysis platform with SCT’s iPSC-derived cardiomyocyte discovery platform, advanced drug leads have been identified in the first of a series of programs. Cancer
The study met its primary endpoint of improving progression-free survival (PFS) compared with dacarbazine treatment. The median PFS on the binimetinib arm was 2.8 months versus 1.5 months
Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments that are currently administered via intravenous infusion. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.